Total acquired shares: 595,400 ordinary shares; total acquisition amount: 1,719,225,643 yen; acquisition period: August 7, 2026 to August 31, 2026; method: market purchase (TSE).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4527","jir_company_name":"Lotte Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4527-20260901-01.pdf","jir_short_summary":"Total acquired shares: 595,400 ordinary shares; total acquisition amount: 1,719,225,643 yen; acquisition period: August 7, 2026 to August 31, 2026; method: market purchase (TSE).","jir_summary":"### Section Heading\nThe notice regarding the status of share buyback clearly states the type of shares to be acquired, total number, total amount, acquisition period, and method. In this case, 595,400 ordinary shares were acquired at 1,719,225,643 yen through market purchases, with the period from August 7 to August 31, 2026. At the board meeting held on March 26, 2026, an upper limit of 1,500,000 shares and up to 30 billion yen was set; to date, the cumulative number of acquired shares remains 595,400 shares, and cumulative acquisition value remains 1,719,225,643 yen.\n\n### Section 2 Heading\nThis is interpreted as an effort to improve capital efficiency while avoiding detriment to shareholder value, and the possibility of additional acquisitions remains pending the remaining upper limit under the resolution. The company intends to secure liquidity and optimize internal capital through market purchases.","jir_financial_highlights":"Total number of acquired shares: 595,400 shares (Unknown)\nTotal acquisition value: 1,719,225,643 yen (Unknown)\nAcquisition period: August 7, 2026 to August 31, 2026 (Unknown)","jir_category":"","jir_hashtags":"#LottePharmaceutical, #ShareBuyback","jir_key_figures":"595,400 shares: Total number of acquired shares\n1,719,225,643 yen: Total acquisition value\nAugust 7, 2026\u2013August 31, 2026: Acquisition period","jir_meta_title":"Lotte Pharmaceutical Co., Ltd. Notice of Share Buyback Status | 2026-09-01","jir_meta_description":"Notice of share buyback status disclosed by Lotte Pharmaceutical Co., Ltd. Providing the exact number of shares acquired, total value, period, and method. Acquisition via market purchases from August 7 to August 31, 2026.","jir_og_title":"Lotte Pharmaceutical Co., Ltd. Notice of Share Buyback Status","jir_og_description":"595,400 ordinary shares acquired at a total of 1,719,225,643 yen via market purchases, acquisition period is 2026-08-07 to 2026-08-31. Cumulative total is the same amount.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7770,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-109556","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n